{"filing":{"accession_number":"0001193125-26-304949","cik":"0001615219","ticker":"DCOY","company_name":"Decoy Therapeutics Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"dcoy-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1615219/000119312526304949/dcoy-20260714.htm"},"events":[{"id":18212,"run_id":16363,"accession_number":"0001193125-26-304949","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on July 14, 2026. The filing reports final voting tallies for three proposals: election of three Class II directors (Patricia Gauthier, Jonathan Lieber, and Frederick E. Pierce), non-binding advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. This is the quintessential shareholder_vote_results event type under Item 5.07.","company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16953,"accession_number":"0001193125-26-304949","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on July 14, 2026. The filing reports final voting tallies for three proposals: election of three Class II directors (Patricia Gauthier, Jonathan Lieber, and Frederick E. Pierce), non-binding advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. This is the quintessential shareholder_vote_results event type under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T21:15:36.211069+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16953,"accession_number":"0001193125-26-304949","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on July 14, 2026. The filing reports final voting tallies for three proposals: election of three Class II directors (Patricia Gauthier, Jonathan Lieber, and Frederick E. Pierce), non-binding advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. This is the quintessential shareholder_vote_results event type under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T21:15:36.211069+00:00","company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","filing_date":"2026-07-15"}]}